Pasar al contenido principal

NUEVOS FACTORES IMPLICADOS EN EL FENOTIPO PSEUDO-ENDOTELIAL DE LAS CELULAS METASTASICAS DURANTE LA HIPOXIA Y SU PAPEL EN LA RESISTENCIA A LA TERAPIA ANTI-ANGIOGENICA

RTI2018-098968-B-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 13
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Emergence of cyclic hypoxia and the impact of PARP inhibitors on tumor progression

  • Conte, Martina
  • Cabeza Fernández, Vanesa
  • Oliver, F. Javier
  • Alarcón Cor, Tomás|||0000-0002-8566-3676
  • Soler, Juan
Tumor hypoxia is a dynamic phenomenon marked by fluctuations in oxygen levels across both rapid (seconds to minutes) and slow (hours to days) time scales. While short hypoxia cycles are relatively well understood, the mechanisms behind longer cycles remain largely unclear. In this paper, we present a novel mechanistic mathematical model that explains slow hypoxia cycles through feedback loops involving vascular expansion and regression, oxygen-regulated tumor growth, and toxic cytokine production. Our study reveals that, for the emergence of slow hypoxia cycles, endothelial cells must adapt by decreasing receptor activation as ligand concentration increases. Additionally, the interaction between tumor cells and toxic cytokines influences frequency and intensity of these cycles. By examining the effects of pharmacological interventions, specifically poly (ADP-ribose) polymerase inhibitors, we also demonstrate how targeting cell proliferation can help regulate oxygen levels. Our findings enhance the understanding of hypoxia regulation and suggest PARP proteins as promising therapeutic targets.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The Multifactorial Role of PARP-1 in Tumor Microenvironment

  • Martí, J. M.
  • Fernández-Cortés, Mónica
  • Serrano-Sáenz, Santiago
  • Zamudio-Martínez, Esteban
  • Delgado-Bellido, Daniel
  • García-Díaz, Ángel
  • Oliver, Francisco Javier
© 2020 by the authors., Poly(ADP-ribose) polymerases (PARPs), represent a family of 17 proteins implicated in a variety of cell functions; some of them possess the enzymatic ability to synthesize and attach poly (ADP-ribose) (also known as PAR) to different protein substrates by a post-translational modification; PARPs are key components in the cellular response to stress with consequences for different physiological and pathological events, especially during neoplasia. In recent years, using PARP inhibitors as antitumor agents has raised new challenges in understanding their role in tumor biology. Notably, the function of PARPs and PAR in the dynamic of tumor microenvironment is only starting to be understood. In this review, we summarized the conclusions arising from recent studies on the interaction between PARPs, PAR and key features of tumor microenvironment such as hypoxia, autophagy, tumor initiating cells, angiogenesis and cancer-associated immune response., This work was supported by Ministerio de Economía y Competividad, Spanish Ministry of Economy and Competitiveness SAF2012-40011-C02-01, SAF2015-70520-R, RTICC RD12/0036/0026, RTI2018-098968-B-I00, CIBER Cáncer ISCIII CB16/12/00421 and Fundación Domingo Martínez to FJO. JMMC, is recipient of a FPI fellowship from Spanish Ministerio de Ciencia; MFC and EZM are recipients of FPU fellowships from the Spanish Ministerio de Ciencia., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Vasculogenic mimicry: Become an endothelial cell “But not so much”

  • Fernández-Cortés, Mónica
  • Delgado-Bellido, Daniel
  • Oliver, Francisco Javier
Blood vessels supply all body tissues with nutrients and oxygen, take away waste products and allow the arrival of immune cells and other cells (pericytes, smooth muscle cells) that form part of these vessels around the principal endothelial cells. Vasculogenic mimicry (VM) is a tumor blood supply system that takes place independently of angiogenesis or endothelial cells, and is associated with poor survival in cancer patients. Aberrant expression of VE-cadherin has been strongly associated with VM. Even more, VE-cadherin has constitutively high phosphorylation levels on the residue of Y658 in human malignant melanoma cells. In this review we focus on non-endothelial VE-cadherin and its post-translational modifications as a crucial component in the development of tumor VM, highlighting the signaling pathways that lead to their pseudo-endothelial and stem-like phenotype and the role of tumor microenvironment. We discuss the importance of the tumor microenvironment in VM acquisition, and describe the most recent therapeutic targets that have been proposed for the repression of VM., This work was supported by the grants from the Spanish Ministry of Economy and Competitiveness SAF2015-70520-R, Fundación Domingo Martínez and the Spanish Ministry of Science and Technology RTI2018-098968-B-I00 and CIBERONC ISCIII CB16/12/00421 to FO.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Enhancing the Bystander and Abscopal Effects to Improve Radiotherapy Outcomes

  • Farias, V. A.
  • Tovar, I.
  • del Moral, Rosario
  • O'Valle, Francisco
  • Expósito, José
  • Oliver, Francisco Javier
  • Ruiz de Almodóvar, José Mariano
In this paper, we summarize published articles and experiences related to the attempt to improve radiotherapy outcomes and, thus, to personalize the radiation treatment according to the individual characteristics of each patient. The evolution of ideas and the study of successively published data have led us to envisage new biophysical models for the interpretation of tumor and healthy normal tissue response to radiation. In the development of the model, we have shown that when mesenchymal stem cells (MSCs) and radiotherapy are administered simultaneously in experimental radiotherapy on xenotumors implanted in a murine model, the results of the treatment show the existence of a synergic mechanism that is able to enhance the local and systemic actions of the radiation both on the treated tumor and on its possible metastasis. We are convinced that, due to the physical hallmarks that characterize the neoplastic tissues, the physical-chemical tropism of MSCs, and the widespread functions of macromolecules, proteins, and exosomes released from activated MSCs, the combination of radiotherapy plus MSCs used intratumorally has the effect of counteracting the pro-tumorigenic and pro-metastatic signals that contribute to the growth, spread, and resistance of the tumor cells. Therefore, we have concluded that MSCs are appropriate for therapeutic use in a clinical trial for rectal cancer combined with radiotherapy, which we are going to start in the near future., This work was supported by the Spanish Ministry of Economy and Competitiveness, MINECO: SAF201240011-C02-02 and SAF2015-70520-R to JR; CNPq, Conselho Nacional de Desenvolvimento Científico e Tecnológico—Brasil to VF; project of Excellence from the Andalusian Regional Government P12CTS-383 to FO; and the Spanish Ministry of Economy and Competitiveness SAF2012-40011-C02-01, SAF2015- 70520-R, RTICC RD12/0036/0026, and CIBER Cáncer ISCIII CB16/12/00421 to FO, VF, and JR.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Endothelial Phosphatase VE-PTP Participates in Vasculogenic Mimicry by Preventing Autophagic Degradation of VE-Cadherin

  • Delgado-Bellido, Daniel
  • Bueno-Galera, Concepción
  • López-Jiménez, L.
  • García-Díaz, Ángel
  • Oliver, Francisco Javier
Aberrant extra-vascular expression of VE-cadherin has been observed in metastasis associated with Vasculogenic Mimicry (VM); we have recently shown that in VM prone cells VE-cadherin is mainly in the form of phospho-VE-cadherin in Y658 allowing increased plasticity that potentiates VM development in malignant cells. In the current study, we present results to show that human malignant melanoma cells VM+, express the VE-cadherin phosphatase VE-PTP. VE-PTP forms a complex with VE-Cadherin and p120-catenin and the presence of this complex act as a safeguard to prevent VE-Cadherin protein degradation by autophagy. Indeed, VE-PTP silencing results in complete degradation of VE-cadherin with the features of autophagy. In summary, this study shows that VE-PTP is involved in VM formation and disruption of VE-PTP/VE-Cadherin/p120 complex results in enhanced autophagy in aggressive VM cells. Thus, we identify VE-PTP as a key player in VM development by regulating VE-cadherin protein degradation through autophagy., This manuscript has been released as a Pre-Print at BiorXiv (https://www.biorxiv.org/content/10.1101/634584v1). This work was supported by the grants from the Spanish Ministry of Economy and Competitiveness SAF2015-70520-R, and the Spanish Ministry of Science and Technology RTI2018-098968-B-I00, CIBERONC ISCIII CB16/12/00421, and Fundación Domingo Martínez to FO.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The PARP Inhibitor Olaparib Modulates the Transcriptional Regulatory Networks of Long Non-Coding RNAs during Vasculogenic Mimicry

  • Fernández-Cortés, Mónica
  • Andrés-León, Eduardo
  • Oliver, Francisco Javier
In highly metastatic tumors, vasculogenic mimicry (VM) involves the acquisition by tumor cells of endothelial-like traits. Poly-(ADP-ribose) polymerase (PARP) inhibitors are currently used against tumors displaying BRCA1/2-dependent deficient homologous recombination, and they may have antimetastatic activity. Long non-coding RNAs (lncRNAs) are emerging as key species-specific regulators of cellular and disease processes. To evaluate the impact of olaparib treatment in the context of non-coding RNA, we have analyzed the expression of lncRNA after performing unbiased whole-transcriptome profiling of human uveal melanoma cells cultured to form VM. RNAseq revealed that the non-coding transcriptomic landscape differed between olaparib-treated and non-treated cells: olaparib significantly modulated the expression of 20 lncRNAs, 11 lncRNAs being upregulated, and 9 downregulated. We subjected the data to different bioinformatics tools and analysis in public databases. We found that copy-number variation alterations in some olaparib-modulated lncRNAs had a statistically significant correlation with alterations in some key tumor suppressor genes. Furthermore, the lncRNAs that were modulated by olaparib appeared to be regulated by common transcription factors: ETS1 had high-score binding sites in the promoters of all olaparib upregulated lncRNAs, while MZF1, RHOXF1 and NR2C2 had high-score binding sites in the promoters of all olaparib downregulated lncRNAs. Finally, we predicted that olaparib-modulated lncRNAs could further regulate several transcription factors and their subsequent target genes in melanoma, suggesting that olaparib may trigger a major shift in gene expression mediated by the regulation lncRNA. Globally, olaparib changed the lncRNA expression landscape during VM affecting angiogenesis-related genes., This research was funded by the Spanish Ministry of Economy and Competitiveness and the Spanish Ministry of Science and Innovation SAF2015-70520- R, RTI2018-098968-B-I00, RTICC RD12/0036/0026 and CIBER Cáncer ISCIII CB16/12/00421, and Fundación Domingo Martínez to F.J.O., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Selective modulation by PARP-1 of HIF-1α-recruitment to chromatin during hypoxia is required for tumor adaptation to hypoxic conditions

  • Martí , Juan Manuel
  • García-Díaz, Ángel
  • Delgado-Bellido, Daniel
  • O’Valle, Francisco
  • González-Flores, Ariannys
  • Carlevaris, Onintza
  • Rodríguez-Vargas, José Manuel
  • Amé, Jean Christophe
  • Dantzer, Françoise
  • King, George L.
  • Dziedzic, Klaudia
  • Berra, Edurne
  • Álava, Enrique de
  • Amaral, Ana Teresa
  • Hammond, Ester M.
  • Oliver, Francisco Javier
[Background] The adaptation to hypoxia is mainly controlled by the HIF transcription factors. Increased expression/activity of HIF-1α correlates with poor prognosis in cancer patients. PARP-1 inhibitors are used in the clinic to treat BRCAness breast/ovarian cancer and have been shown to regulate the hypoxic response; therefore, their use could be expanded., [Methods] In this work by integrating molecular/cell biology approaches, genome-wide ChIP-seq, and patient samples, we elucidate the extent to which PARP-1 exerts control over HIF-1-regulated genes., [Results] In human melanoma, PARP-1 and HIF-1α expression are strongly associated. In response to a hypoxic challenge poly(ADP-ribose) (PAR) is synthesized, HIF-1α is post-transcriptionally modified (PTM) and stabilized by PARylation at specific K/R residues located at its C-terminus. Using an unbiased ChIP-seq approach we demonstrate that PARP-1 dictates hypoxia-dependent HIF-recruitment to chromatin in a range of HIF-regulated genes while analysis of HIF-binding motifs (RCGTG) reveals a restriction on the recognition of hypoxia responsive elements in the absence of PARP-1. Consequently, the cells are poorly adapted to hypoxia, showing a reduced fitness during hypoxic induction., [Conclusions] These data characterize the fine-tuning regulation by PARP-1/PARylation of HIF activation and suggest that PARP inhibitors might have therapeutic potential against cancer types displaying HIF-1α over-activation., This work was supported by Junta de Andalucía, project of Excellence from Junta de Andalucía P10-CTS-0662, P12-CTS-383 to FJO, Spanish Ministry of Economy and Competitiveness SAF2012-40011-C02-01, SAF2015-70520- R, RTI2018-098968-B-I00, RTICC RD12/0036/0026 and CIBER Cáncer ISCIII CB16/12/00421 to FJO. EB1s lab is supported by the Basque Department of Industry, Tourism and Trade (Etortek) and the MINECO (CB16/12/00421) grants. Fundación Domingo Martínez (call 2019)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Glioblastoma cells counteract PARP inhibition through Pro-Survival induction of lipid droplets synthesis and utilization

  • Majuelos-Melguizo, Jara
  • Rodríguez-Vargas, José Manuel
  • Martínez-López, Nuria
  • Delgado-Bellido, Daniel
  • García-Díaz, Ángel
  • Yuste, Víctor J.
  • García-Macía, Marina
  • López, Laura M.
  • Singh, Rajat
  • Oliver, Francisco Javier
Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor in adults. Poly (ADP-ribose) polymerase inhibitors (PARPi) represent a new class of anti-neoplastic drugs. In the current study, we have characterized the mechanism by which glioblastoma cells evade the effect of PARPi as anti-tumor agents. We have found that suppression of PARP activity exerts an anti-stemness effect and has a dual impact on autophagy, inducing its activation in the first 24 h (together with down-regulation of the pro-survival mTOR pathway) and preventing autophagosomes fusion to lysosomes at later time-points, in primary glioma cells. In parallel, PARPi triggered the synthesis of lipid droplets (LDs) through ACC-dependent activation of de novo fatty acids (FA) synthesis. Notably, inhibiting β-oxidation and blocking FA utilization, increased PARPi-induced glioma cell death while treatment with oleic acid (OA) prevented the anti-glioma effect of PARPi. Moreover, LDs fuel glioma cells by inducing pro-survival lipid consumption as confirmed by quantitation of oxygen consumption rates using Seahorse respirometry in presence or absence of OA. In summary, we uncover a novel mechanism by which glioblastoma escapes to anti-tumor agents through metabolic reprogramming, inducing the synthesis and utilization of LDs as a pro-survival strategy in response to PARP inhibition., This research was funded by Junta de Andalucía, Project of Excellence P10-CTS-0662, P12- CTS-383 to FJO, Spanish Ministry of Economy and Competitiveness SAF2012-40011-C02-01, SAF2015-70520- R, RTI2018-098968-B-I00, RTICC RD12/0036/0026 and CIBER Cancer ISCIII CB16/12/00421 to FJO.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

VE-Cadherin in Cancer-Associated Angiogenesis: A Deceptive Strategy of Blood Vessel Formation

  • Delgado-Bellido, Daniel
  • Oliver, Francisco Javier
  • Vargas Padilla, María Victoria
  • Lobo Selma, Laura
  • Chacón-Barrado, Antonio
  • Díaz-Martín, J.
  • Álava, Enrique de
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)., Tumor growth depends on the vascular system, either through the expansion of blood vessels or novel adaptation by tumor cells. One of these novel pathways is vasculogenic mimicry (VM), which is defined as a tumor-provided vascular system apart from endothelial cell-lined vessels, and its origin is partly unknown. It involves highly aggressive tumor cells expressing endothelial cell markers that line the tumor irrigation. VM has been correlated with high tumor grade, cancer cell invasion, cancer cell metastasis, and reduced survival of cancer patients. In this review, we summarize the most relevant studies in the field of angiogenesis and cover the various aspects and functionality of aberrant angiogenesis by tumor cells. We also discuss the intracellular signaling mechanisms involved in the abnormal presence of VE-cadherin (CDH5) and its role in VM formation. Finally, we present the implications for the paradigm of tumor angiogenesis and how targeted therapy and individualized studies can be applied in scientific analysis and clinical settings., E.d.Á. laboratory is supported by ISCIII-FEDER (PI20/00003, and PMP22/00054) to E.d.Á., Consejería de Salud y Consumo, Junta de Andalucía (PE-0186-2018) to E.d.Á. and (PI-0061-2020) to E.d.Á., ECAEC222952DEAL, Fundación Científica AECC to E.d.Á, GEIS-Fundación Mari Paz Jiménez Casado (Beca Trienal a la Investigación en Sarcomas) to J.D.-M., Fundación CRIS Contra el Cáncer, Asociación Pablo Ugarte, Fundación María García Estrada, and CIBERONC. This work was supported by grants from the Spanish Ministry of Economy and Competitiveness SAF2015-70520-R, the Spanish Ministry of Science and Technology RTI2018-098968-B-I00, CIBERONC ISCIII CB16/12/00421 and Junta de Andalucía, a project of Excellence from Junta de Andalucía P10-CTS-0662, P12-CTS-383 to F.O. Fundación Domingo Martínez to F.O. Consejería de Economía, Innovación, Ciencia y Empleo, Junta de Andalucía (PAIDI 2020, POSTDOC_ 21_00865) to D.D.-B. Fundación Getthi ONC18PE01/2022 to E.d.Á., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Emergence of cyclic hypoxia and the impact of PARP inhibitors on tumor progression

  • Conte, Martina
  • Cabeza Fernández, Vanesa
  • Oliver, Francisco Javier
  • Alarcón, Tomás
  • Soler, Juan
Tumor hypoxia is a dynamic phenomenon marked by fluctuations in oxygen levels across both rapid (seconds to minutes) and slow (hours to days) time scales. While short hypoxia cycles are relatively well understood, the mechanisms behind longer cycles remain largely unclear. In this paper, we present a novel mechanistic mathematical model that explains slow hypoxia cycles through feedback loops involving vascular expansion and regression, oxygen-regulated tumor growth, and toxic cytokine production. Our study reveals that, for the emergence of slow hypoxia cycles, endothelial cells must adapt by decreasing receptor activation as ligand concentration increases. Additionally, the interaction between tumor cells and toxic cytokines influences frequency and intensity of these cycles. By examining the effects of pharmacological interventions, specifically poly (ADP-ribose) polymerase inhibitors, we also demonstrate how targeting cell proliferation can help regulate oxygen levels. Our findings enhance the understanding of hypoxia regulation and suggest PARP proteins as promising therapeutic targets., The research in this paper has been performed while MC was a research fellow at the Department of Mathematical Sciences “G.L. Lagrange” of the Politecnico of Torino (Italy). This paper has been partially supported by the State Research Agency of the Spanish Ministry of Science and Innovation and European Regional Development Fund through the project (PID2022-137228OB-I00 MICIU/AEI/10.13039/501100011033) and by ERDF, EU (JS, MC). It has been also supported by the Modeling Nature Research Unit, Grant QUAL21-011 (JS, MC, FJO) funded by Consejería de Universidad, Investigación e Innovación (Junta de Andalucía), by the State Research Agency of the Spanish Ministry of Science and Innovation and European Regional Development Fund, project RTI2018-098968-B-I00 (FJO), by the Junta de Andalucía P20_01179 (FJO), and the Fundación Domingo Martínez (call 2019) (FJO). Moreover, it has been supported by the grant PID2021-127896OB-I00, funded by MCIN/AEI/ 10.13039/ 501100011033 ‘ERDF A way of making Europe’ (TA), by the Spanish Research Agency through the Severo Ochoa and Maria de Maeztu Program for Centers and Units of Excellence in R& D awarded to the Centre de Recerca Matemàtica (CEX2020-001084-M) (TA), by the Italian Ministry of Education, Universities and Research, through the MIUR grant Dipartimento di Eccellenza 2018-2022, project E11G18000350001 (MC), and by the National Group of Mathematical Physics (GNFM-INdAM) through the INdAM-GNFM Project (CUP E53C22001930001) “From kinetic to macroscopic models for tumor-immune system competition” (MC). The work has been performed in the frame of the project PRIN 2022 PNRR Mathematical Modelling for a Sustainable Circular Economy in Ecosystems (P2022PSMT7, CUP D53D23018960001) funded by the European Union - NextGenerationEU and by MUR-Italian Ministry of Universities and Research (MC). The authors thank also the Isaac Newton Institute for Mathematical Sciences for support and hospitality during the program Mathematics of movement: an interdisciplinary approach to mutual challenges in animal ecology and cell biology under EP-SRC grant number EP/R014604/1 (TA) and CERCA Program/Generalitat de Catalunya for institutional support (TA)., With funding from the Spanish government through the "Unit of Excellence Maria de Maeztu" accreditation (CEX2020-001084-M)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Chromosomal 3p loss and 8q gain drive vasculogenic mimicry via HIF-2α and VE-cadherin activation in uveal melanoma

  • Delgado-Bellido, Daniel
  • Chacon, Antonio
  • Olmedo-Pelayo, Joaquín
  • Jordán Perez, Carmen
  • Gilabert-Prieto, Paula
  • Díaz-Martín, Juan
  • García-Díaz, Ángel
  • Oliver, Francisco Javier
  • Álava, Enrique de
Uveal melanoma (UM) is the most common primary intraocular malignant tumor in adults and is where Vasculogenic Mimicry (VM) was first described. VM enables aggressive cancer cells to independently form blood networks, complicating treatment for patients exhibiting VM. Previous studies linked VE-Cadherin phosphorylation at Y658 to gene expression via Focal Adhesion Kinase (FAK), enhancing the Kaiso/β-catenin/TCF-4 complex associated with VE-Cadherin and thereby promoting VM. Recently, an allosteric HIF-2α inhibitor (Belzutifan) was FDA-approved for VHL-associated ccRCCs. In this research, we elucidate the primary causes of VM formation in UM patients with chromosome 3p loss and chromosome 8q gain, identifying VHL, BAP1, and FAK as important factors driving VM and worsening prognosis. These factors promote abnormal activation of HIF-2α and VE-Cadherin under basal hypoxic conditions, leading to VM formation. Cytoscan 750k experiments on the MUM 2B cell line reveal a loss of chromosome 3p, where the VHL, BAP1, and CTNNB1 genes are located, and a gain of chromosome 8q (FAK), whereas the MUM 2C cell line shows a gain of chromosome 3p. This provides an outstanding cross-sectional model from patient samples to established cell lines for VM studies. LC-MS experiments demonstrate that VE-Cad/ENG expression is related to FAK activity in UM cell lines. Finally, using a combination of Belzutifan (HIF-2α inhibitor) and FAK inhibitor (FAKi), we observed a significant reduction in UM xenografts. Our results lead us to propose combining Belzutifan and FAKi as a personalized treatment strategy for UM patients. This approach inhibits VM formation and counters the initial hypoxic conditions resulting from chromosome 3p loss and chromosome 8q gain in UM patients, instilling confidence in the potential of this treatment strategy., EdÁ laboratory is supported by ISCIII-FEDER (PI20/00003, and PMP22/00054) to EdÁ, Consejería de Salud y Consumo, Junta de Andalucía (PE-0186-2018) to EdÁ and (PI-0061-2020) to EdÁ, ECAEC222952DEAL, Fundación Científica AECC to EdÁ, GEIS-Fundación Mari Paz Jiménez Casado (Beca Trienal a la Investigación en Sarcomas) to EdÁ, Fundación CRIS Contra el Cáncer, Asociación Pablo Ugarte, Fundación María García Estrada, and CIBERONC. Fundación Getthi ONC18PE01/2022 to EdÁ. This work was supported by grants from the Spanish Ministry of Economy and Competitiveness SAF2015-70520-R, the Spanish Ministry of Science and Technology RTI2018-098968-B-I00, CIBERONC ISCIII CB16/12/00421 and Junta de Andalucía, a project of Excellence from Junta de Andalucía P10-CTS-0662, P12-CTS-383 to FJO. Fundación Domingo Martínez to FJO and GD-A. Consejería de Economía, Innovación, Ciencia y Empleo, Junta de Andalucía (PAIDI 2020, POSTDOC_ 21_00865) to DD-B., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Tankyrases modulate the hypoxia response through non-catalytic mechanisms affecting HIF-1α

  • Zamudio-Martínez, Esteban
  • Delgado-Bellido, Daniel
  • Borrego-Pérez, Jerónimo
  • García-Díaz, Ángel
  • Herrera Campos, Ana Belén
  • Rodríguez-Vargas, José Manuel
  • Oliver, Francisco Javier
Adaptation to hypoxia is essential for cancer survival and is linked to poor prognosis and treatment resistance. This adaptation triggers the expression of genes that promote angiogenesis and metabolic reprogramming, collectively enhancing cancer cell survival, tumor growth, migration and metastasis. Consequently, there is an urgent need for innovative strategies to inhibit tumor adaptation to hypoxic conditions., This work was supported by Projects and RTI2018-098968‐B‐I00, PID2022-136220OB-I00 and PID2023-1525166OA-100 financed by The Spanish Ministry of Economy and Competitiveness, The Spanish Ministry of Science and Innovation and by FEDER “A way of making Europe”; Project of Excellence from Junta de Andalucía PY20_01179; CIBER Cáncer ISCIII CB16/12/00421; and Fundación Domingo Martínez (Call 2019) to FJO and JMRV., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Glioblastoma Cells Counteract PARP Inhibition through Pro-Survival Induction of Lipid Droplets Synthesis and Utilization

  • Majuelos-Melguizo, Jara|||0000-0003-1841-1345
  • Rodríguez-Vargas, José Manuel|||0000-0001-8141-1693
  • Martínez-López, Nuria|||0000-0002-8220-6015
  • Delgado-Bellido, Daniel|||0000-0002-9588-4747
  • García-Díaz, Ángel
  • Yuste, Victor José|||0000-0001-5322-9261
  • García-Macía, Marina|||0000-0002-3908-9060
  • López, Laura M.
  • Singh, Rajat
  • Oliver, F. J.|||0000-0001-8468-1998
Glioblastoma multiforme (GBM) is the most common and deadly primary brain tumor in adults and one of the most aggressive cancers. The use of Poly ADP-Ribose Polymerase (PARP) inhibitors is being expanded as therapeutic alternative in multiple types of cancer beyond BRCA1/2 mutant breast and ovarian cancer. Here we have analyzed glioma cells' traits that limit the efficacy of PARPi as anti-glioma agents and we found that PARPi triggered the synthesis of lipid droplets (LDs) that fueled glioma cells by inducing pro-survival lipid consumption. Notably, blocking Fatty Acids utilization by inhibition of β-oxidation with etomoxir, increased PARPi-induced glioma cell death while treatment with oleic acid (OA) prevented the anti-glioma effect of PARPi. We uncover a novel mechanism by which glioblastoma escapes to anti-tumor agents through metabolic reprogramming, inducing the synthesis and utilization of LDs as a pro-survival strategy in response to PARP inhibition. Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor in adults. Poly (ADP-ribose) polymerase inhibitors (PARPi) represent a new class of anti-neoplastic drugs. In the current study, we have characterized the mechanism by which glioblastoma cells evade the effect of PARPi as anti-tumor agents. We have found that suppression of PARP activity exerts an anti-stemness effect and has a dual impact on autophagy, inducing its activation in the first 24 h (together with down-regulation of the pro-survival mTOR pathway) and preventing autophagosomes fusion to lysosomes at later time-points, in primary glioma cells. In parallel, PARPi triggered the synthesis of lipid droplets (LDs) through ACC-dependent activation of de novo fatty acids (FA) synthesis. Notably, inhibiting β-oxidation and blocking FA utilization, increased PARPi-induced glioma cell death while treatment with oleic acid (OA) prevented the anti-glioma effect of PARPi. Moreover, LDs fuel glioma cells by inducing pro-survival lipid consumption as confirmed by quantitation of oxygen consumption rates using Seahorse respirometry in presence or absence of OA. In summary, we uncover a novel mechanism by which glioblastoma escapes to anti-tumor agents through metabolic reprogramming, inducing the synthesis and utilization of LDs as a pro-survival strategy in response to PARP inhibition.